Zinc involvement in opioid addiction and analgesia – should zinc supplementation be recommended for opioid-treated persons?
Open Access
- 4 August 2015
- journal article
- review article
- Published by Springer Nature in Substance Abuse Treatment, Prevention, and Policy
- Vol. 10 (1) , 29
Abstract
Zinc chelators were shown to facilitate some opioid-withdrawal signs in animals. Zinc deficiency, which affects more than 15 % the world’s population, is also common among opioid consumers and opioid-treated animals exhibit misbalances of zinc distribution. The present study focuses on how zinc ions interfere with opioid dependence/addiction and analgesia, trying to preliminary discuss if zinc supplementation in opioid-users should be recommended in order to reduce the risk of addiction. All relevant literature was searched up to April 2015. The search was performed using the term “zinc” plus combinations of following terms: “opioid receptors”, “opioid” or representatives of this class, “addiction”, “dependence”, “analgesia”, and “pain”. Human, animal, in vitro studies and reviews were including. Both human and animal studies revealed decreased serum zinc under opioid-administration conditions, attributed mainly to increased urinary elimination (humans) or redistribution (animals). Moreover, animal studies revealed decreased brain zinc levels in morphine-treated animals, with increased zinc hepatic levels, but also an enhancement of endogenous opioid system activity and a possible reduction of morphine withdrawal by zinc. In vitro studies revealed reduction of opioid ligands binding to receptors by zinc. However, the very few in vivo animal studies on opioid analgesia revealed controversial results, as zinc demonstrated clear analgesic effect, but zinc associated to opioids doesn’t result in a potentiation of the analgesic effect. Zinc dietary supplementation in patients treated with opioids for cancer-related chronic pain should be considered, due to the high incidence of zinc deficiency, also well-documented in opioid consumers. The low toxicity of orally-administered zinc also pleads for this idea. The main contra-argument to zinc administration in opioid-treated persons is related to the way zinc influences opioid-induced analgesia.Keywords
This publication has 109 references indexed in Scilit:
- Cancer cachexia—pathophysiology and managementJournal of Gastroenterology, 2013
- Estimating the Global Prevalence of Zinc Deficiency: Results Based on Zinc Availability in National Food Supplies and the Prevalence of StuntingPLOS ONE, 2012
- The Relationship between Zinc Intake and Serum/Plasma Zinc Concentration in Children: A Systematic Review and Dose-Response Meta-AnalysisNutrients, 2012
- The impact of opioid analgesics on the gastrointestinal tract function and the current management possibilities [Polish version: Wpływ opioidowych środków przeciwbólowych na czynność układu pokarmowego oraz aktualne możliwości postępowania terapeutycznego p. 132]Contemporary Oncology, 2012
- Zinc: an essential but elusive nutrientThe American Journal of Clinical Nutrition, 2011
- Concerted action of zinc and ProSAP/Shank in synaptogenesis and synapse maturationThe EMBO Journal, 2011
- Modulation of Neuronal Signal Transduction and Memory Formation by Synaptic ZincFrontiers in Behavioral Neuroscience, 2011
- Relationship between Painful Crisis and Serum Zinc Level in Children with Sickle Cell AnaemiaAnemia, 2010
- The Hallucinogen N,N -Dimethyltryptamine (DMT) Is an Endogenous Sigma-1 Receptor RegulatorScience, 2009
- Stereoselective action of (+)-morphine over (−)-morphine in attenuating the (−)-morphine-produced antinociception via the naloxone-sensitive sigma receptor in the mouseEuropean Journal of Pharmacology, 2007